



PHARMA-BIO
PARTNERING
—FORUMS—

Focusing on the Right Partners



Inaugural

Early Stage Molecular Diagnostics Partnering Forum

February 19-20, 2012

InterContinental San Francisco Hotel

Particularly efficient for promoting discussion of partnerships, the **Early Stage Molecular Diagnostics Partnering Forum** is designed for both the emerging companies with promising technology and applications, and more established companies looking to collaborate with these companies.

Enabling Next-Generation, Predictive Diagnostics with the SnapPath™ Live Tumor Testing System

Adam Schayowitz, Director of Business Development,
BioMarker Strategies, LLC

BioMarker Strategies has developed a novel cancer diagnostic platform that uses fresh tumor biopsy samples to enable next-generation predictive tests to guide targeted therapeutic selection. The SnapPath™ platform is an automated, live solid tumor cell processing device that evokes first-in-class, functional ex vivo biomarkers. By modulating a patient's tumor sample outside of their body, SnapPath™ generates phosphoprotein-based Functional Signaling Profiles (FSPs) that reveal information about the signal transduction networks to predict patient response to targeted drug therapy. SnapPath™ moves beyond traditional genomic profiling of fixed tissue to enable a new level of stratification and profiling of cancer patients.

Program Advisory Board Includes:

- Abbott Molecular
- BD Diagnostics
- BioMerieux
- Bristol Myers Squibb
- DAKO
- Diaceutics
- Genomic Health
- Gen-Probe
- Illumina
- LabCorp
- Leomics Consulting
- MDX Consulting
- Medco Health Solutions
- QIAGEN
- Roche Diagnostics
- Scientia Advisors
- SONY DADC
- Versant Ventures

Part of: 19th International

 **Molecular Med
TRI-CON 2012**

Moscone North Convention Center
San Francisco, CA

February 19-23

 Organized by
Cambridge Healthtech Institute

TriConference.com